transplantation, to more fully mimic the Berlin patient protocol, and thereby evaluate whether a graft-versus-reservoir effect is necessary for full eradication. Meanwhile, the differing outcomes for both the Berlin and Boston patients, although highlighting the pernicious nature of the HIV-1 reservoirs and the formidable challenges that HIV-1 eradication strategies face, also provide impetus for the continued development of therapeutic interventions that include the introduction of HIV-resistant cells.
With this in mind, efforts are underway to mimic this aspect of the therapy by engineering autologous T cells or hematopoietic stem cells to be HIV-resistant, and enormous progress has been made in developing techniques to render cells resistant to HIV-1 (ref. 10 ). These include methods that specifically create CCR5-negative cells, through the use of either RNA interference or zinc-finger nuclease (ZFN) technologies 11, 12 .
Last month, Tebas et al. 13 reported results from the first small trial evaluating CCR5 gene disruption by ZFNs, in which 12 HIV-positive patients underwent adoptive transfer of autologous CD4 T cells that had been treated ex vivo with an adenoviral vector encoding ZFNs targeting CCR5. Some intriguing indications of efficacy were observed. For example, although viremia recurred in all patients for whom antiretroviral therapy was transiently interrupted and was accompanied by an expected decrease in CD4 T-cell levels, the decline in the levels of CCR5-modified cells was significantly less pronounced than for the total T-cell population. In addition, one study participant, later found to be heterozygous for the CCR5D32 allele, managed to fully control his viremia during the intervention. This observation fits with the requirement for biallelic CCR5 disruption to achieve HIV resistance, which would be easier to achieve in this genetic background. Current methods to deliver ZFNs to T cells and hematopoietic stem cells result in 33-40% bialleleic disruption in the edited cells 14, 15 , but more efficient ZFN delivery or expression may be required to increase this frequency for individuals with two functional copies of CCR5.
Ultimately, it is not yet known whether HIV-resistant cells will be effective in the autologous setting, without the accompanying chemoablation or GVHD that could reduce infected cell reservoirs. However, it should also be possible to engineer HIV-resistant stem cells for patients requiring allogeneic and at least a functional cure, although the duration of remission needed before proclaiming a permanent or sterilizing cure is unknown. Indeed, in the absence of such information, a more suitable description of the Berlin patient's ongoing status might be 'longterm remission' rather than 'cure' .
Following analytical treatment interruption, it is now apparent that neither Boston patient had achieved complete viral eradication during their cancer treatments, although their HIV-1 rebounded more slowly than is typical. In hindsight, this outcome may not be all that surprising, given the variety of outcomes that follow allogeneic transplantation in patients with malignant hematologic diseases. Here, a graft-versus-leukemia effect is often an essential component to effectively eradicate or control any remaining cancer, but understanding the factors that can influence the outcome has proven challenging 8 . Similarly, in HIV-positive transplant recipients, the effectiveness of a donor graftversus-HIV-reservoir effect could also be expected to be variable. In addition, although infected memory CD4 + T cells have been identified as an important reservoir of the virus that persists during cART 1 , other viral reservoirs, including non-T cells, may not be destroyed by an allogeneic response.
Although their HIV-1 was not eradicated, a question that arises in the case of the Boston patients is whether the treatment they received could nonetheless have reduced their HIV-1 reservoirs and provided clinical benefit, even without reaching the status of a cure? Smaller HIV-1 reservoirs are associated with reduced pathologic sequelae, such as inflammation, that occur even with effective cART control of viremia 9 . However, this potential beneficial effect would continue only under cover of cART; once the Boston patients were removed from this pharmacological safety net, any reactivation of HIV-1 from remnants of their original reservoirs would readily infect the donor-derived cells, effectively mimicking a primary HIV-1 infection, and potentially seeding more extensive viral reservoirs. Such a scenario means that the risks and benefits for analytical treatment interruption in such patients need to be carefully considered and discussed.
The failure of the Boston patients to maintain HIV-1 suppression off cART reveals that even the intense cytoablative conditioning and GVHD that they experienced did not fully eradicate all HIV-1 reservoirs, and that transplantation of HIV-resistant cells from the CCR5D32 donor was likely an essential component in the salutary outcome for the Berlin patient.
The time is ripe for an ethics of entrepreneurship
To the Editor: Entrepreneurship has been hailed as an important engine for economic growth, productivity, innovation and employment. During the recent economic crisis, entrepreneurship has been cited as the key to reducing unemployment, unleashing the potential of the social economy, and delivering on the promise of new biomedical and green technologies (http://www.oecd.org/cfe/leed/ leedprojectsyoucanjoinin2011-2012.htm). In higher education, entrepreneurship programs have become the fastest-growing field of study on campus and have resulted in the emergence
academic entrepreneur weighs the value of personal wealth against the value of seeing her research doing the most good in the world? If a venture capitalist offers funding with the proviso that a startup would have to abandon a line of research originally funded by the NIH to benefit a certain group of sick people, what should the entrepreneur do? These can be difficult choices with justice implications, and they raise questions as to whether federal funding serves the best interests of the public.
We argue that these actions have major social, legal and ethical consequences that remain largely unexplored by ethics and social science scholars, and as a result, we see substantial gaps in our knowledge of what we term the 'ethics of entrepreneurship' . Using social science approaches to examine how the entrepreneur actually acts in these situations may reveal the answers to these questions. Studies in business entrepreneurship examine the shift from closed to open innovation systems, the efficiencies at transferring university-assigned inventions to the private sector, and the benefits and costs of technology transfer offices 6, 7 . We note that nowhere in the entrepreneurship literature is the practice of ethics examined as a key research question. Similarly, ethics scholarship focuses on the outcomes that result from tensions at the academic-industry interface. Topics include how professional conflicts result from industrial support of basic and clinical research, and how ties between companies and physicians affect patient care 8, 9 . Other research looks at how private funding in academia can produce broader institutional conflicts and radically change the mission of the modern research university 10 
As the modern research university changes how it values the entrepreneurial spirit and its impact on scholarship, this constrains the ethical choices that academic actors might make. Academic entrepreneurs must balance the need for confidentialityknow-how, trade secrets and patents are the coin of the realm for any new venture-with long-held traditions of openness, sharing and collaboration. Should some negative results be shared with potential investors, even though there would be no expectation to publish them in academic journals? Macro-level effects come into play, too. The decisions of academic entrepreneurs profoundly affect the trajectory of new technologies. Matters of cost, price, time, feasibility and leadership are the central focus of early decisions in the life cycle of a startup company. However, deciding the ethical nuance in such deliberations requires a set of skills with different levels of intrinsically subjective judgments. What kind of expertise can plausibly settle the social and ethical importance of, say, whether to license broadly or exclusively? Develop diagnostic tests for classes of disease that have no effective therapies? Found a stem cell bank when the therapeutic utility of the cells are unknown? Calculations of risks and benefits by entrepreneurs during the startup phase of a company may have lasting ethical consequences. How much should one 'talk up' the potential of the company's technology during a road show? Should knowledge of a potentially competing technology be disclosed to funders? What tradeoffs are made as an of a new academic discipline 1 . Driven by the US Bayh-Dole Act of 1980-which gives ownership of intellectual property to federally funded universities-and deep government funding cuts facing their researchers, research universities are increasingly using industry support to sustain research projects. They promote technology transfer as a means of justifying public support. The tone from Washington supports these trends. The alignment of key interests enables the development of new drugs and the creation of new bioindustries, and helps advance new initiatives, such as the US National Institutes of Health (NIH) National Center for Advancing Translational Sciences, which Francis Collins calls a "new paradigm for translational research that involves government, academia, industry, philanthropy and patient advocacy groups" 2 .
Indeed, entrepreneurial activities are held as metrics of success for universities as well as for faculty and students. For example, a recent survey listed an impressive number of revenue-producing Stanford University startup companies 3 . The university proudly claimed these company successes as indicative of its own and held up the entrepreneurial alumni as products of its educational mission. Universities are actively promoting a culture of entrepreneurship for their faculty and students by developing technology licensing offices, centers of entrepreneurship and startup resources. Stanford University, for example, recently announced it was investing in its own inventors using StartX, a local nonprofit incubator partnered with the university. Stanford expects to distribute up to $150 million through StartX in exchange for equity stakes in incubator-supported companies 4 . And promotion and tenure committees increasingly use commercial and entrepreneurial activities as measurements of success 5 .
These new initiatives signal exciting times for the modern research university. But they also bring new social and ethical complexities. The most pressing questions surround the academic entrepreneur. With one foot in academia and the other in industry, the entrepreneur faces a tricky balancing act. Student inventors, their academic advisors and thesis committee members may be partners or co-founders in the same commercial venture. And the details of these partnerships may need to be hammered out long before the student graduates. Who is listed on the patent, what role they will take in the new enterprise and how much ownership they will receive become tangled with pressures on students to disclose research results and to finish their degree at every stage of the commercialization process and must transcend our commonly held reliance on regulation and oversight.
In sum, scholarship in entrepreneurship should broaden its focus to study the ethical choices of key social actors along the entrepreneurial pipeline and observe how entrepreneurs actually practice ethics. Research should look across disciplines to identify how key ethical principles and values are defined and used by different actors at each stage of the early commercial pathway. This research could result in an overarching ethics framework to guide academic entrepreneurs throughout the process of commercialization. In this way, entrepreneurial decisions become more ethical, leading to more efficient and beneficial regulatory outcomes. Such a framework has the potential to integrate ethics from idea to initial public offering and would provide a universal vocabulary for the ethical deliberation of entrepreneurial actors. Knowledge from this research could help redefine early life sciences ventures as socially responsible entities that are founded and run by individuals who think as deeply about morals as they do about money and markets.
The third way of umbilical cord blood banking quality control or be developed into a product. The banks collaborate with scientists in research institutes, hospitals and universities to provide the cells for transplantation, clinical trial and basic research. Breakthroughs in research and clinical trials ensure that the units are used efficiently. The cord blood donation program is supported by the income from the family banking program, which costs $2,500-3,500 to store one unit for 20 years, and from the release fee of the units for allogeneic transplants, which cost $7,000-30,000. This model has been adopted by Covina, California-based company StemCyte, and the national licensed cord blood banks in China.
A second hybrid model, and a variation on this theme, is the 'donatable family banking (Cún juān hù lì)' model. In this model, the cord blood units are family banked, but they can be searched by the wider public. Parents sign a commercial contract and pay a fee for the collection and storage of their child's cord blood sample. Units are tested, processed and typed for human leukocyte antigen (HLA). The cord blood units in the public bank are tested for the same disease markers as the donated units. HLA typing data are published on international registries and are available for searches for matches. If a unit is matched, the parents can decide whether they want to keep their cord blood unit, sell it or donate it to the patient in need of an allogeneic transplant. Donatable family banking overcomes the problem with family-banked samples, which cannot be used in searches or circulated, even though the likelihood that a family will ever use the unit is low. It is estimated that the inventory in private cord blood banks is double or triple that in the public banks 3 . This model opens a window for the public into the privately banked units, so that the units that have been collected and typed can be used more efficiently. In Asia, this model has been adopted by Bionet (BabyBanks) in Taiwan and Shanghai Cord Blood Bank in China.
In the above arrangements, ownership and accessibility of the units vary. In the public and private combination model, the company has ownership of the donated cord blood. The bank can provide the cells quickly for transplant because the cells are 'on the shelf ' . For example, StemCyte has facilitated more than 1,700 cord blood transplants globally, out of 29,000 donated cord blood units. In contrast, in the donatable family banking model, the cells belong to the customers. Banks using this model need to seek consent from the customer before a unit can be released.
Apart from clinical use of stem cells, these cord blood banks collaborate with One hybrid is the 'public and private combination' model. In this arrangement, an organization runs both a cord blood donation program and a family banking program. The bank has ownership of the donated cord blood, and the family-banked cord blood belongs to the customer. The donated cells can be used for therapy, basic research, animal studies, clinical trials, system monitoring,
